These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20586990)

  • 41. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
    Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
    Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Kantarjian H; O'Brien S; Shan J; Huang X; Garcia-Manero G; Faderl S; Ravandi-Kashani F; Verstovsek S; Beth Rios M; Cortes J
    Cancer; 2008 Feb; 112(4):837-45. PubMed ID: 18085610
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality of life on imatinib.
    Hahn EA; Glendenning GA
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):31-6. PubMed ID: 12783373
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
    Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
    Cortes J; O'Brien S; Quintas A; Giles F; Shan J; Rios MB; Talpaz M; Kantarjian H
    Cancer; 2004 Jun; 100(11):2396-402. PubMed ID: 15160343
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
    Li N; Zheng B; Cai HF; Yang J; Luo XF; Weng LZ; Zhan FM; Liu MB
    Clin Drug Investig; 2018 Jan; 38(1):79-86. PubMed ID: 29027641
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
    Meng FY; Zheng WY; Liu XL; Xu B; Song LL; Zhang Y; Huang F
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1149-50. PubMed ID: 14625174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
    Kimura S; Kako S; Wada H; Sakamoto K; Ashizawa M; Sato M; Terasako K; Kikuchi M; Nakasone H; Okuda S; Yamazaki R; Oshima K; Nishida J; Watanabe T; Kanda Y
    Leuk Res; 2011 Jan; 35(1):e11-2. PubMed ID: 20952061
    [No Abstract]   [Full Text] [Related]  

  • 52. Development of a population-based cost-effectiveness model of chronic graft-versus-host disease in Spain.
    Crespo C; Pérez-Simón JA; Rodríguez JM; Sierra J; Brosa M
    Clin Ther; 2012 Aug; 34(8):1774-87. PubMed ID: 22835778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
    Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
    J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.
    Sheng G; Chen S; Dong C; Zhang R; Miao M; Wu D; Tan SC; Liu C; Xiong T
    J Med Econ; 2017 Apr; 20(4):371-381. PubMed ID: 27936995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Imatinib mesylate--a new oral targeted therapy.
    Savage DG; Antman KH
    N Engl J Med; 2002 Feb; 346(9):683-93. PubMed ID: 11870247
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
    J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
    Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
    Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
    Garside R; Round A; Dalziel K; Stein K; Royle P
    Health Technol Assess; 2002; 6(33):1-162. PubMed ID: 12633529
    [No Abstract]   [Full Text] [Related]  

  • 59. Imatinib for chronic myeloid leukaemia: a NICE mess.
    Rajaratnam G; Edwards J
    Lancet; 2001 Dec; 358(9296):1902. PubMed ID: 11741655
    [No Abstract]   [Full Text] [Related]  

  • 60. An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.
    Wu B; Liu M; Li T; Lin H; Zhong H
    Medicine (Baltimore); 2017 Jul; 96(29):e7445. PubMed ID: 28723754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.